US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Professor of Medicine
Department of Medical Oncology
Washington University School of Medicine
St Louis, Missouri
Editorial Director, Hematology/Oncology
Senior Managing Editor
This program is intended for physicians and other healthcare professionals who provide care for patients with lymphomas.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 17, 2016, through February 16, 2017:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.
Ruxolitinib plus thalidomide achieved objective disease improvements in patients with myelofibrosis in phase II study from ASH 2018 reported by Clinical Care Options (CCO).
Results from the CASSINI study of rivaroxaban for VTE prophylaxis in ambulatory patients with cancer from ASH 2018 reported by Clinical Care Options (CCO).
Phase III RV-MM-PI-0752 study on optimizing lenalidomide/dexamethasone for elderly patients with newly diagnosed MM from ASH 2018 reported by Clinical Care Options (CCO).
Data from phase III ECHELON-2 trial of brentuximab vedotin plus CHP in untreated CD30+ PTCL from ASH 2018, reported by Clinical Care Options (CCO).
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.